{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:51:47Z","timestamp":1792176707496,"version":"4.4.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Adoptive cell therapy (ACT), a key direction in tumor immunotherapy, has achieved remarkable progress in recent years. This paper systematically reviews the current status and future trends of ACT, covering lymphokine-activated killer cells (LAK), tumor-infiltrating lymphocytes (TIL), cytokine-induced killer cells (CIK), dendritic cells (DC), T cell receptor-modified T cells (TCR-T), chimeric antigen receptor T cells (CAR-T), natural killer (NK) cells, chimeric antigen receptor-modified NK cells (CAR-NK), and the emerging CAR-M. The paper focuses on emerging technological approaches, including universal CAR structural optimization, iPSC-derived cell products, multifunctional CAR design, and AI-assisted antigen screening. It also compares differences among various cell therapies in antigen specificity, efficacy persistence, safety, and clinical application challenges. The core contribution of this paper lies in synthesizing recent research advances to propose strategies for addressing tumor heterogeneity, antigen escape, cell persistence, and therapeutic safety in ACT. This provides a reference for future personalized and precision cell therapy approaches.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1665488","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:28:18Z","timestamp":1758518898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Recent advances in adoptive cell therapy for cancer immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiameng","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science."},{"key":"B2","article-title":"Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice","volume":"29","author":"Fefer","year":"1969","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.152.4.823","article-title":"Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes","volume":"152","author":"Fernandez-Cruz","year":"1980","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ni1001-957","article-title":"Immunotherapy through TCR gene transfer","volume":"2","author":"Kessels","year":"2001","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823","article-title":"Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes","volume":"155","author":"Grimm","year":"1982","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2024.2418321","article-title":"The future of cellular therapy for the treatment of renal cell carcinoma","volume":"2024","author":"Chaoul","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell therapy with TILs: training and taming T cells to fight cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944927","article-title":"Editorial: first regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs) - lifileucel (Amtagvi)","volume":"30","author":"Parums","year":"2024","journal-title":"Med Sci Monit"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00848-w","article-title":"Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma","volume":"21","author":"Klobuch","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"2538-","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.125.1.238","article-title":"In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors","volume":"125","author":"Yron","year":"1980","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.125.4.1487","article-title":"The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors","volume":"125","author":"Lotze","year":"1980","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1479-5876-11-83","article-title":"Cytokine-induced killer cells promote antitumor immunity","volume":"11","author":"Jiang","year":"2013","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.138.8.2728","article-title":"Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta","volume":"138","author":"Ochoa","year":"1987","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.11.019","article-title":"A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma","volume":"11","author":"Leemhuis","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic Malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29827","article-title":"Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy","volume":"235","author":"Zhang","year":"2020","journal-title":"J Cell Physiol"},{"key":"B29","article-title":"Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells","volume":"26","author":"Jiang","year":"2006","journal-title":"Anticancer Res"},{"key":"B30","first-page":"3997","article-title":"Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer","author":"Wu","year":"","journal-title":"Anticancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182948452","article-title":"Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients","volume":"36","author":"Huang","year":"2013","journal-title":"J Immunother."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s40425-019-0696-8","article-title":"PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer","volume":"7","author":"Zhou","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130620","article-title":"Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1186\/s12967-024-05940-y","article-title":"Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Jiang","year":"2024","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-032414-112334","article-title":"T cell antigen receptor recognition of antigen-presenting molecules","volume":"33","author":"Rossjohn","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201696003","article-title":"Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes","volume":"36","author":"Tkach","year":"2017","journal-title":"EMBO J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81137","article-title":"Dendritic cell-derived exosomes for cancer therapy","volume":"126","author":"Pitt","year":"2016","journal-title":"J Clin Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28549","article-title":"Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro","volume":"64","author":"Rao","year":"2016","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ni.3294","article-title":"Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses","volume":"17","author":"Halim","year":"2016","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/32588.","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature."},{"key":"B44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.20471\/acc.2019.58.s2.13","article-title":"CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER","volume":"58","author":"\u0160amija","year":"2019","journal-title":"Acta Clin Croat."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c09653","article-title":"Biomimetic dendritic cell-based nanovaccines for reprogramming the immune microenvironment to boost tumor immunotherapy","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","first-page":"101229","DOI":"10.1016\/j.xcrm.2023.101229","article-title":"Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine","volume":"4","author":"Dan","year":"2023","journal-title":"Cell Rep Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2024034","article-title":"The recent advancement of TCR-T cell therapies for cancer treatment","volume":"56","author":"Zhao","year":"2024","journal-title":"Acta Biochim Biophys Sin (Shanghai)."},{"key":"B50","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","article-title":"Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation","volume":"23","author":"Palacios","year":"2004","journal-title":"Oncogene."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04839-2","article-title":"Deciphering the immunopeptidome in vivo reveals new tumour antigens","volume":"607","author":"Jaeger","year":"2022","journal-title":"Nature."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T cell therapies: A comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1533033819831068","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: A systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bulcan.2022.10.001","article-title":"New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients","volume":"110","author":"Gaillard","year":"2023","journal-title":"Bull Cancer."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene autoleucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658753","article-title":"Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/hum.2015.054","article-title":"CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma","volume":"26","author":"Enblad","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells","volume":"22","author":"Levine","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008275","article-title":"CARs are sharpening their weapons","volume":"12","author":"Pievani","year":"2024","journal-title":"J Immunother Cancer."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ejh.14335","article-title":"Comparative analysis of bispecific antibodies and CAR T-cell therapy in follicular lymphoma","volume":"114","author":"Morabito","year":"2025","journal-title":"Eur J Haematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2024.2399365","article-title":"Single center, real-world retrospective study of CAR-T cell therapy for relapsed\/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven","volume":"79","author":"Brijs","year":"2024","journal-title":"Acta Clin Belg."},{"key":"B72","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell Malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological Malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000032","article-title":"CAR T cells for solid tumors: armed and ready to go","volume":"20","author":"Kakarla","year":"2014","journal-title":"Cancer J"},{"key":"B76","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-015-0122-9","article-title":"Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer","volume":"29","author":"Hillerdal","year":"2015","journal-title":"BioDrugs."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18575","article-title":"Generation of B7-H3 isoform regulated by ANXA2\/NSUN2\/YBX1 axis in human glioma","volume":"28","author":"Shen","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12672-024-01455-6","article-title":"Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches","volume":"15","author":"Ramalingam","year":"2024","journal-title":"Discov Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","article-title":"CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes","volume":"15","author":"Jilani","year":"2024","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbz023","article-title":"Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations","volume":"2","author":"Hong","year":"2019","journal-title":"Precis Clin Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28657","article-title":"NK cells: An attractive candidate for cancer therapy","volume":"234","author":"Valipour","year":"2019","journal-title":"J Cell Physiol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46080528","article-title":"Apoptotic receptors and CD107a expression by NK cells in an interaction model with trophoblast cells","volume":"46","author":"Mikhailova","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41698-023-00356-1","article-title":"Advances in NK cell therapy for brain tumors","volume":"7","author":"Fares","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.06.048","article-title":"Research progress of chimeric antigen receptor modified NK cells in the treatment of acute myeloid leukemia \u2013review","volume":"31","author":"Peng","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2024.05.004","article-title":"Recent advances and progress in immunotherapy of solid cancers","volume":"164","author":"Kumar","year":"2024","journal-title":"Adv Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454427","article-title":"Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis","volume":"15","author":"Park","year":"2024","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer."},{"key":"B90","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine."},{"key":"B91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","article-title":"Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients","volume":"23","author":"Ahmadvand","year":"2023","journal-title":"BMC Cancer."},{"key":"B93","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40164-024-00576-6","article-title":"Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879452","article-title":"A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma","volume":"13","author":"Bae","year":"2022","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000429","article-title":"HIV-specific ADCC improves after antiretroviral therapy and correlates with normalization of the NK cell phenotype","volume":"68","author":"Jensen","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000877","article-title":"HIV\/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses","volume":"80","author":"Sun","year":"2024","journal-title":"Hepatology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.humimm.2021.09.004","article-title":"Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice","volume":"83","author":"Ghasemzadeh","year":"2022","journal-title":"Hum Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cells13231976","article-title":"Advances in induced pluripotent stem cell-derived natural killer cell therapy","volume":"13","author":"Qiao","year":"2024","journal-title":"Cells."},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2023.03.018","article-title":"Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy","volume":"27","author":"Chang","year":"2023","journal-title":"Bioact Mater"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-022-09330-8","article-title":"Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance","volume":"71","author":"Yadav","year":"2023","journal-title":"Immunol Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.04.015","article-title":"Activation of AMPA receptor promotes TNF-\u03b1 release via the ROS-cSrc-NF\u03baB signaling cascade in RAW264.7 macrophages","volume":"461","author":"Cheng","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309194","article-title":"Abandoning M1\/M2 for a network model of macrophage function","volume":"119","author":"Nahrendorf","year":"2016","journal-title":"Circ Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1088\/1741-2552\/acc54e","article-title":"Low-intensity pulsed ultrasound increases neurotrophic factors secretion and suppresses inflammation inin vitromodels of peripheral neuropathies","volume":"20","author":"Fontana","year":"2023","journal-title":"J Neural Eng."},{"key":"B108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","article-title":"M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors","volume":"21","author":"Huo","year":"2023","journal-title":"J Transl Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.ebiom.2022.103873","article-title":"CAR-macrophage: An extensive immune enhancer to fight cancer","volume":"76","author":"Wang","year":"2022","journal-title":"EBioMedicine."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"key":"B113","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol Cancer."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.64.4.419","article-title":"Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives","volume":"64","author":"Andreesen","year":"1998","journal-title":"J Leukoc Biol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"biomark Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fimmu.2015.00263","article-title":"Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages","volume":"6","author":"Ch\u00e1vez-Gal\u00e1n","year":"2015","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1532833","article-title":"CAR-macrophages: tailoring cancer immunotherapy","volume":"15","author":"Chettri","year":"2024","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"B123","doi-asserted-by":"publisher","first-page":"110111","DOI":"10.1016\/j.celrep.2021.110111","article-title":"Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity","volume":"37","author":"Tang","year":"2021","journal-title":"Cell Rep"},{"key":"B124","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.xcrm.2025.102079","article-title":"Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-1087","article-title":"From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapies","volume":"14","author":"Zhang","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"200817","DOI":"10.1016\/j.omton.2024.200817","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2021.09.003","article-title":"Synthetic receptors for logic gated T cell recognition and function","volume":"74","author":"Simon","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01153-x","article-title":"Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy","volume":"21","author":"Zhu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci Adv"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf302","article-title":"Computational methods and data resources for predicting tumor neoantigens","volume":"26","author":"Zhao","year":"2025","journal-title":"Brief Bioinform"},{"key":"B132","doi-asserted-by":"publisher","first-page":"25151355241305856","DOI":"10.1177\/25151355241305856","article-title":"Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives","volume":"12","author":"Shahzadi","year":"2024","journal-title":"Ther Adv Vaccines Immunother."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing logic gates for safer immunotherapy of cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1665488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:28:21Z","timestamp":1758518901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1665488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":133,"alternative-id":["10.3389\/fimmu.2025.1665488"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1665488","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1665488"}}